Metformin Hydrochloride Stada

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Stada, is a biguanide presented as a tablet for oral use. It reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby lowering blood glucose levels in adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Hydrochloride Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability for healthcare providers. The product complies with European Union pharmaceutical standards and is manufactured under strict GMP conditions.

Metformin Hydrochloride is indicated for conditions related to impaired glucose metabolism and is used primarily in the management of type 2 diabetes. - Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes: delays progression to type 2 diabetes when combined with lifestyle modification. - Polycystic ovary syndrome: improves insulin resistance and may help regulate menstrual cycles (off‑label use).

Metformin Hydrochloride may cause a range of adverse reactions, most of which are related to the gastrointestinal system.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhea: loose stools, often transient. - Metallic taste: temporary alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: marked elevation of liver enzymes.

When prescribing Metformin Hydrochloride, clinicians should consider several safety precautions to minimize risk. - Renal function: assess eGFR before initiation and periodically thereafter. - Hepatic function: avoid use in patients with significant liver disease. - Lactic acidosis risk: contraindicated in conditions associated with hypoxia or severe heart failure. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Alcohol consumption: limit intake as alcohol may increase lactic acidosis risk. - Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may cause acute kidney injury, raising metformin levels. - Cimetidine: can increase metformin plasma concentration. - Alcohol: excessive intake raises risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Sulfonylureas: combined use can increase hypoglycemia risk.